Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.

Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...

A German pharmaceutical company is acquiring a drug developer with operations in Research Triangle Park.

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...